Seminal vesicles

Biological Dynamics to deliver showcase presentation at Precision Medicine World Conference

Retrieved on: 
Tuesday, January 24, 2023
Oncology, Health, Biometrics, Genetics, Clinical Trials, Biotechnology, MBA, Master of Science, Biomarker, Cancer, Blood, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Patient, Georgetown University, Seminal vesicles, Exosome, HPB, Liquid biopsy, Conference, PDAC, Medicine, UCSD, Medical imaging, MD

Biological Dynamics , a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced today that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine World Conference (PMWC) in Santa Clara, Calif.

Key Points: 
  • Biological Dynamics , a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced today that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine World Conference (PMWC) in Santa Clara, Calif.
    Dr. Dhani’s PMWC showcase presentation on January 26th is part of the Clinical Utility of Liquid Biopsies track.
  • Biological Dynamics’ ExoVerita platform targets extracellular vesicles in blood, isolating exosomes to detect biomarkers of early-stage cancers.
  • “Leveraging the innovations of our ExoVerita platform, we are developing solutions for patients, their families and the medical community.
  • He also holds a Master’s in Clinical Research from UCSD and anticipates completing his MBA from Georgetown University in 2025.

Biological Dynamics Appoints Industry Veteran Peter Wulff as Chief Financial Officer

Retrieved on: 
Tuesday, January 17, 2023
EVS, Financial management, Seminal vesicles, MD, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Intellectual property, Growth, Cancer, Exosome, SAN, Doctor of Philosophy, Investment, Pharmaceutical industry

SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Biological Dynamics , Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.

Key Points: 
  • SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Biological Dynamics , Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.
  • Mr. Wulff has over 35 years of financial management experience in both public and privately held companies in emerging growth life sciences.
  • He most recently served as Chief Financial Officer at JenaValve Technology, where he played an instrumental role in the corporate relocation from Germany and subsequent growth of its US operations.
  • "I am honored to join Biological Dynamics, and look forward to enhancing efforts to drive adoption of our novel and proprietary technology for early disease detection," said Peter Wulff.

Unchained Labs finds the Lenti Leprechaun at the end of the rainbow

Retrieved on: 
Tuesday, January 17, 2023
Confusion, Disease, Genome, Cell, Seminal vesicles, Marketing, ELISA, Fluorescence, SVP, PCR, Lenti, Frustration, Lentivirus, Interferometry, Fine chemical, Vaccine

Researchers need to know how many Lenti's they've made and confirm that they have the right structure.

Key Points: 
  • Researchers need to know how many Lenti's they've made and confirm that they have the right structure.
  • Most researchers use single-component assays like ELISA to measure the capsid titer or PCR to measure the genome titer.
  • Both assays require Lenti to be broken apart, provide only one piece of the puzzle and neither confirms if they ever had the right structure.
  • "Until now, measuring a meaningful Lenti titer was almost impossible and full of confusion and frustration," said Taegen Clary, SVP of Marketing at Unchained Labs.

Unchained Labs finds the Lenti Leprechaun at the end of the rainbow

Retrieved on: 
Tuesday, January 17, 2023
Confusion, Disease, Genome, Cell, Seminal vesicles, Marketing, ELISA, Fluorescence, SVP, PCR, Lenti, Frustration, Lentivirus, Interferometry, Fine chemical, Vaccine

Researchers need to know how many Lenti's they've made and confirm that they have the right structure.

Key Points: 
  • Researchers need to know how many Lenti's they've made and confirm that they have the right structure.
  • Most researchers use single-component assays like ELISA to measure the capsid titer or PCR to measure the genome titer.
  • Both assays require Lenti to be broken apart, provide only one piece of the puzzle and neither confirms if they ever had the right structure.
  • "Until now, measuring a meaningful Lenti titer was almost impossible and full of confusion and frustration," said Taegen Clary, SVP of Marketing at Unchained Labs.

United States Patent Office Allows Patent to Exosome Biomedical Company Nurexone

Retrieved on: 
Friday, January 13, 2023
NRX, Cell, PTEN, PCT, Patent, CVE, TSX Venture Exchange, Seminal vesicles, Meeting, FRA, Invention, Sirna, Patient, Plan, Exosome, Tel Aviv University, IP, Pharmaceutical industry

HAIFA, Israel and CALGARY, Alberta, Jan. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CVE) (J90:FRA) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application NO.

Key Points: 
  • HAIFA, Israel and CALGARY, Alberta, Jan. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CVE) (J90:FRA) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application NO.
  • The Patent covers and protects NurExone Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment.
  • The Company intends to file additional patent applications with the USPTO as well as additional international patent applications (PCT) in order to further strengthen NurExone’s intellectual property portfolio.
  • The Patent was submitted by the Technion-Israel Institute of Technology and Ramot, a Tel Aviv University's technology transfer company and is part of NurExone’s licensed intellectual property portfolio.

ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

Retrieved on: 
Tuesday, December 27, 2022
Science, Seniors, Biotechnology, Research, Pharmaceutical, Health, Consumer, Clinical Trials, University of Delaware, Clinical trial, PD, Insulin resistance, Central nervous system, Timeline of Genesis patriarchs, Nature Communications, Protein, Phosphoprotein, Research, Neurodegeneration, National Institute on Aging, DNA, Brain, Biomarker, NIA, Inflammation, Trial of the century, Metabolism, Tissue, Patient, Plasma, Seminal vesicles, Pathology, Neuron, University, Kinesiology, Aging Cell, NEV, Ageing, Human, Paper, ChromaDex, AD, RNA, Cell, Pharmaceutical industry, Medical imaging, Medical device, NEVS

The study investigated whether NR would positively augment nicotinamide adenine dinucleotide (NAD+) levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles (NEVs) found in blood plasma.

Key Points: 
  • The study investigated whether NR would positively augment nicotinamide adenine dinucleotide (NAD+) levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles (NEVs) found in blood plasma.
  • NEVs are nano-sized particles that are released by neurons in the central nervous system, including the brain, and circulate in blood plasma.
  • The present study demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
  • Such results are promising and will set the foundation for further research evaluating NR supplementation in neurodegenerative disorders.

Insights on the Exosome Therapeutics Global Market to 2035 - Featuring Cellular Biomedicine, Codiak BioSciences, Coya Therapeutics and Curexsys Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Pharmaceutical, Health, Element, Chronic pain, Administration, Therapy, Research, Geography, COVID-19, Business, Inflammation, Regeneration, R, Gustave Roussy, MSC, EVS, Growth, Seminal vesicles, Infection, Exosome, Q5, IND, Eskişehir Osmangazi University, Disease management, Innovation management measurement, Cell, ILIAS, Pharmaceutical industry, Medical device, Healthcare, Distribution (marketing), Management, Sport, USD

What is the current market landscape and recent trends in the exosome therapeutics domain?

Key Points: 
  • What is the current market landscape and recent trends in the exosome therapeutics domain?
  • The exosome therapeutics market is presently growing at a significant pace among the dynamic sectors of pharmaceutical industry.
  • The factors contributing to the growth of exosome therapeutics market include increasing disease burden, rise in research and development activities for exosome therapeutics, and government funding for the production of such therapeutics.
  • In terms of route of administration, the market is likely to be driven by exosome therapeutics designed for intravenous administration.

MITOSENSE AND UPPSALA UNIVERSITY'S CENTRE FOR TRANSPLANTATION TECHNOLOGY ENTER INTO STRATEGIC MEMORANDUM OF UNDERSTANDING

Retrieved on: 
Wednesday, December 21, 2022
Human, Amyotrophic lateral sclerosis, MOT, Cell, Memorandum, Uppsala University Hospital, Mitochondrion, Mitochondrial disease, Disease, Seminal vesicles, Uppsala University, TBI, Traumatic brain injury, Neurodegeneration, Huntington's disease, Injury, EVS, Multimedia, Alzheimer's disease, Myocardial infarction, Parkinson's disease, ALS, Microsoft, Professor, MOU, Medicine, Pharmaceutical industry

MitoSense, Inc.'s medical technology is focused on harnessing the power of mitochondria to treat a variety of diseases.

Key Points: 
  • MitoSense, Inc.'s medical technology is focused on harnessing the power of mitochondria to treat a variety of diseases.
  • Mitochondria Organelle Transplantation (MOT™) technology is a first-in-kind, patented technology that utilizes mitochondria isolated from human tissue and transfers them into specific cells to mitigate disease.
  • Mitochondria Organelle Transplantation (MOT)™ technology is based on the concept that restoring mitochondrial function in diseased cells by transferring healthy mitochondria will improve cellular energy production and cell health.
  • The Memorandum of Understanding (MOU) will initiate a collaboration between Uppsala University's CTTM and MitoSense.

Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt

Retrieved on: 
Friday, December 16, 2022
Confidentiality, Asthma, EV, Clinical trial, Inflammatory bowel disease, Inflammation, Failure, T helper 17 cell, Partnership, Atopic dermatitis, Security (finance), Marketing, Allergy, Psoriasis, TH1, Risk, Growth, EVS, Research, COVID-19, Seminal vesicles, Patient, Arthritis, Pharmaceutical industry, Horizon

The $45 million term loan, which provides for three years of interest-only payments followed by a two-year amortization period, replaces the Company’s existing senior secured debt which would have begun amortizing in March 2023.

Key Points: 
  • The $45 million term loan, which provides for three years of interest-only payments followed by a two-year amortization period, replaces the Company’s existing senior secured debt which would have begun amortizing in March 2023.
  • “Their pipeline candidates EDP1815 and EDP2939, in development for atopic dermatitis and psoriasis, are great examples of the potential of SINTAX medicines.
  • Evelo Biosciences is a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects.
  • Horizon Technology Finance Corporation (NASDAQ: HRZN) is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries.

Funding Renewed for Biotech Center, LSU One of Five Partners

Retrieved on: 
Tuesday, December 6, 2022
Precision medicine, Acquisition, Ion, Exosome, CBM2, Plastic, Nanofluidic circuitry, DNA, Mechanical, Stroke, University of Kansas Medical Center, Liquid biopsy, Mechanical engineering, Urine, National Cancer Institute, University, Wake Forest School of Medicine, LSU, University of North Carolina at Chapel Hill, Disease management, Children's Mercy Hospital, Cerebrospinal fluid, Research, Biomarker, Cancer, Infection, Blood, Seminal vesicles, Nanopore sequencing, Pharmaceutical industry, Renewable energy, Medicine

CBM2’s partners include LSU, the University of Kansas, the University of Kansas Medical Center, University of North Carolina-Chapel Hill, and Wake Forest School of Medicine.

Key Points: 
  • CBM2’s partners include LSU, the University of Kansas, the University of Kansas Medical Center, University of North Carolina-Chapel Hill, and Wake Forest School of Medicine.
  • The total amount of the center’s renewed five-year grant is nearly $6 million, while the LSU portion of the funds is just over $2 million.
  • LSU is represented in the center by Mechanical Engineering Professors Sunggook Park and Michael Murphy.
  • Also, the micro- and nanomanufacturing technologies that we are developing in LSU will contribute to the manufacturing sector of Louisiana industries.”